Edgewise Therapeutics (NASDAQ:EWTX) is building itself up as a good long-term biotech to hang onto. Especially, when you consider that it was able to report positive results from its phase 2 ...

Edgewise Networks will significantly improve the security of east-west communication by verifying the identity of application software, services and processes, Zscaler said. Zscaler has purchased ...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders ...

BOULDER, Colo. - Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a biopharmaceutical company specializing in muscle disease treatment with a market capitalization of $2.91 billion and an impressive 393 ...

We can readily understand why investors are attracted to unprofitable companies. For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming ...

Additionally, Edgewise is set to report significant data from its Phase 2 studies in Duchenne muscular dystrophy in the first half of 2025, which will further guide their Phase 3 planning.

BOULDER, Colo., January 13, 2025--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming ...